Journal
Peptide news, explained
A daily briefing on peptide science, regulation and industry: new studies, FDA actions, pipeline updates and what they mean for researchers. Plain English, primary sources linked, no hype.
RSS feed41 posts
Trump Officials Weigh Letting Pharmacies Compound Peptides
The Trump administration is drafting a plan to let pharmacies compound unapproved peptides without writing new FDA rules, over agency scientists' objections.
FDARegulationQuality & testingIndustry
The World Anti-Doping Agency Still Won't Ban GLP-1 Drugs
WADA's 2027 list keeps semaglutide and tirzepatide off its ban, even as a physician survey finds real concern about non-medical use in sport.
GLP-1Anti-dopingRegulationStudy
Swiss Police Seized Over 3,200 Vials of Illegal Peptides in One Raid
Police near Basel seized over 3,200 vials of unregulated peptides, Switzerland's largest such find, as regulators trace 80% of flagged shipments to Poland.
Gray marketAnti-dopingQuality & testingRegulation
Why a 70-Year-Old Peptide Chemistry Firm Is Worth $1.8 Billion
Samsung Biologics is paying a 40% premium, about $1.8 billion, for a Swiss peptide manufacturer, betting that peptide-making capacity itself has become scarce.
IndustryManufacturingPipeline
South Korea Approved a GLP-1 Drug Sanofi Had Given Up On
Hanmi won approval for efpeglenatide, the obesity drug Sanofi returned in 2020 — a year before a trial showed it protected hearts and kidneys.
RegulationGLP-1IndustryPipeline
A Painful Limb-Fat Disorder Still Gets Mistaken for Obesity
A new review says lipedema, a limb-fat disorder in women, is routinely misclassified as obesity by BMI alone — and may carry different metabolic risk entirely.
Metabolic researchExplainerGLP-1Study
Diabetes Still Blunts Weight Loss, Even on the Newest Peptide Drug
In a 1,152-person trial, Lilly's retatrutide cut weight up to 20.8% in diabetics — less than the 28-30% seen without diabetes.
GLP-1Metabolic researchPipelineStudy
Two Men Charged in a Transnational Counterfeit Semaglutide Ring
Federal prosecutors charged two men with smuggling counterfeit semaglutide from China, down to fake needles and pen labels. Each faces up to 71 years.
Gray marketRegulationFDAQuality & testing
Adding a Third Hormone to Tirzepatide Lifted Weight Loss to 23%
In a 367-person trial, adding the amylin peptide eloralintide to tirzepatide pushed average weight loss to 23.3%, against 14.8% for tirzepatide alone.
GLP-1Metabolic researchPipelineStudy
Nail Detachment Is Four Times More Common on GLP-1 Drugs
A 1,904-person study found nail detachment in 39% of GLP-1 drug users versus 9% of matched non-users — the first controlled look at the link.
GLP-1StudyExplainer
An Oral Peptide Pill Kept Psoriasis Clear Through Two Years
A swallowed peptide pill kept 70% of psoriasis patients clear at two years, and 89% clear at the genital skin that usually responds worst.
StudyPipelineExplainer
Boehringer's Dual-Hormone Peptide Hit Two Targets in a Diabetes Trial
In a 755-person trial, survodutide activated a hormone receptor that normally raises blood sugar, yet cut weight 13.1% and improved glycemic control.
GLP-1Metabolic researchPipelineStudy
Scientists Resurrected a 160-Million-Year-Old Antimicrobial Peptide
Researchers rebuilt a 160-million-year-old immune peptide. A single amino-acid change explains most of its bacteria-killing power.
Antimicrobial peptidesStudyExplainer
A Peptide That's Scarcer in Alzheimer's Brains Cut Damage in Mice
Catestatin, a peptide the body already makes, runs low in Alzheimer's brain tissue. Giving it back to mice reduced tau, amyloid and brain inflammation.
StudyLongevity researchExplainer
A slower-acting cancer peptide made immunotherapy work in mice
A synthetic peptide that ruptures tumor cells in two deliberately timed stages made checkpoint-blockade immunotherapy much more effective in mice.
StudyPipelineExplainer
Roche's peptide pushed 62% of trial patients to normal blood sugar
In a 447-person trial, Roche's experimental peptide enicepatide brought 62% of participants with type 2 diabetes into normal blood-sugar range within a year.
GLP-1PipelineStudyIndustry
CagriSema beat tirzepatide on weight loss even as Novo's stock fell
Novo Nordisk's CagriSema outweighed Eli Lilly's tirzepatide in a head-to-head diabetes trial. Investors sent Novo's shares down anyway.
GLP-1PipelineIndustryStudy
GLP-1 Diabetes Drugs Linked to Fewer Alzheimer's Diagnoses
A 153,000-patient records study found fewer Alzheimer's diagnoses after starting a GLP-1 drug — but the design can't show why.
GLP-1StudyMetabolic researchLongevity research
UCLA reviewed 565 peptide studies. Two-thirds were in animals.
A UCLA review of 565 studies on six popular peptides found the human evidence thin, and one MK-677 trial was stopped over heart-failure risk.
StudyRecovery researchQuality & testingExplainer
Peptide vendors' crypto payments: $4 million in 2024, $100 million now
Chainalysis projects crypto payments to peptide vendors will pass $100 million in 2026, from $4 million in 2024. Here's why Johns Hopkins physicians are worried.
Gray marketQuality & testingIndustryRegulation
About this journal Each post reports on published research, public regulatory actions and company announcements, with the sources linked. It is not medical advice, and nothing here is a claim about any product Torrey Labs supplies. Read the peptide guide for the basics, or look up a lot's certificate of analysis.
Research use only All products supplied by Torrey Labs are sold for laboratory research use only by qualified professionals. They are not drugs, foods, cosmetics, or medical devices, are not approved by the FDA, and must not be administered to humans or animals. No product is offered for the diagnosis, treatment, cure, or prevention of any condition, and no medical claims are made.